Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process

Area of Science:

• Oncology
• Inflammation Biology
• Pharmacology

Background:

• Cancer development and progression are complex processes influenced by genetic mutations and the tumor microenvironment.
• Chronic inflammation and platelet activation at sites of injury are increasingly recognized as critical factors in tumorigenesis.
• Existing strategies for cancer prevention primarily focus on genetic factors, leaving a gap in addressing microenvironmental influences.

Purpose of the Study:

• To review the evidence linking chronic inflammation and platelet activation to cancer development and progression.
• To explore the rationale for using anti-inflammatory and antiplatelet agents as a novel approach for cancer chemoprevention.
• To highlight the role of low-dose aspirin in preventing colorectal cancer (CRC).

Main Methods:

• Review of existing clinical studies and experimental animal models.
• Analysis of biological mechanisms connecting inflammation, platelet function, and tumorigenesis.
• Examination of pharmacological data on anti-inflammatory and antiplatelet agents.

Main Results:

• Malignant tumors frequently arise in tissues with chronic inflammation and platelet activity.
• Anti-inflammatory drugs and antiplatelet agents, such as low-dose aspirin, can potentially inhibit cancer initiation and progression.
• Strong evidence supports the chemopreventive effect of low-dose aspirin against colorectal cancer.

Conclusions:

• Modulating inflammation and platelet responses represents a promising strategy for cancer prevention.
• Pharmacological interventions targeting these pathways, including low-dose aspirin, offer a viable approach to curb tumorigenesis.
• The U.S. Preventive Services Task Force recommends low-dose aspirin for the primary prevention of cardiovascular disease and colorectal cancer, underscoring its therapeutic potential.